A Phase 1 interventional study of [¹⁴C]-LY4515100 Oral Solution and LY4515100 Tablet in Healthy, sponsored by Eli Lilly and Company. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate how the body handles [¹⁴C]-LY4515100. The study will investigate how much [¹⁴C]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes [¹⁴C]-LY4515100 so that it can be used or removed, and how the body gets rid of [¹⁴C]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\[¹⁴C\]-LY4515100 containing radioactivity administered orally
Drug: [¹⁴C]-LY4515100 Oral Solution
LY4515100 administered orally with \[¹⁴C\]-LY4515100 containing radioactivity administered intravenously (IV)
Drug: LY4515100 Tablet · Drug: [¹⁴C]-LY4515100 IV
\[¹⁴C\]-LY4515100 administered orally
LY4515100 administered orally
\[¹⁴C\]-LY4515100 administered IV
Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time frame: Predose Up to Day 14
Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Time frame: Predose Up to Day 14
Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100
Time frame: Predose Up to Day 14
Part 1: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
Time frame: Predose Up to Day 14
Part 1: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
Time frame: Predose Up to Day 14
Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air
Time frame: Predose Up to Day 14
Part 1: Total Number of Metabolites of LY4515100 in Urine, Feces, and Plasma
Time frame: Predose Up to Day 14
Part 2: PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of [¹⁴C]-LY4515100
Time frame: Predose Up to Day 9
Part 2: PK: Maximum Concentration (Cmax) of [¹⁴C]-LY4515100
Time frame: Predose Up to Day 9
Part 2: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity
Time frame: Predose Up to Day 9
Part 2: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity
Time frame: Predose Up to Day 9
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY4515100